Skip to main content

Horizon Discovery to Develop Drug Sensitivity Panel for DxS

NEW YORK (GenomeWeb News) – Horizon Discovery said today that it will develop a panel of human isogenic cell models of drug sensitivity and resistance mechanisms in cancer patients for DxS to use in its pharmacogenetic program.

DxS will use the panel to continue to develop its TheraScreen clinical diagnostic kits.

Horizon will use its gene engineering technology, called GENESIS, to generate a range of mutant and normal cell lines that will serve as a source of DNA that will be used to assess the performance of the TheraScreen K-RAS Mutation Kits, which are used to determine which patients will respond to anti-EGFR targeted colorectal cancer treatments, including Erbitux and Vectibix.

"Our initial focus will be on evaluating new diagnostic kits from DxS using isogenic human mutant vs. normal DNA-controls, which we feel represent a 'gold-standard' means of bench-marking companion diagnostics where mutations often need to be detected in humans within a background of excess isogenic normal DNA," Horizon's CEO, Chris Torrance, said in a statement.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.